Robert Blum

President and CEO, Cytokinetics · Person

Mentions

Episodes

Claims

Robert Blum - President and CEO, Cytokinetics. Tracked across 11 mentions in podcasts and expert conversations analyzed by Sonic.

What Robert Blum has said

The United States is ceding its competitive advantage in biotechnology to China due to China's deliberate strategic commitment to industrializing the sector.

bearish·Robert Blum

A growing distrust in science has recently emerged in the United States.

bearish·Robert Blum

The lack of a U.S. national vision for science and medicine has become a more acute problem over the last 2 to 3 years.

bearish·Robert Blum

The United States is ceding its competitive advantage in biotechnology to China due to China's deliberate strategic commitment to industrializing the sector.

Expert perspectiveRobert BlumJul 22

A growing distrust in science has recently emerged in the United States.

Expert perspectiveRobert BlumJul 22

The lack of a U.S. national vision for science and medicine has become a more acute problem over the last 2 to 3 years.

Expert perspectiveRobert BlumJul 22

Biopharmaceutical companies such as Genentech, Amgen, Vertex, and Regeneron required 20 to 30 years to achieve their current scale.

Expert perspectiveRobert BlumJul 22

The erosion of U.S. pharmaceutical leadership begins with the commoditization of pharmaceutical ingredients and extends through the supply chain to clinical trials and medicine availability.

Expert perspectiveRobert BlumJul 22

The United States lacks a national industrial policy and commitment to science and medicine, making it harder to build biotech companies.

Expert perspectiveRobert BlumJul 22

Cytokinetics launched its first commercial medicine earlier this year.

Expert perspectiveRobert BlumJul 22

The first commercial drug from Cytokinetics is a treatment for obstructive hypertrophic cardiomyopathy.

Expert perspectiveRobert BlumJul 22

Cytokinetics incurred a net operating deficit of $3 to $4 billion over its 28-year history to reach the point of commercialization.

Expert perspectiveRobert BlumJul 22

Cytokinetics' business model is based on commercializing scientific research that was initially supported by federal funding for academic institutions.

Expert perspectiveRobert BlumJul 22

It would be far more difficult to build a company like Cytokinetics today than when it was founded.

Expert perspectiveRobert BlumJul 22

Create a free account to see Robert Blum's full intelligence report - every claim, the relationship network, and AI Q&A across all sources. No card needed.

Get started free

Back to Entities Entity Detail